Relay's CEO said its PI3K alpha mutant-selective asset, Zovega, is moving into three pivotal trials, including a second-line breast cancer trial expected to be fully enrolled by mid-2027. The company reported $849 million of cash, which should last well into 2029. Relay plans an update on vascular anomalies data at ASH in December.
RLAY · Relay Therapeutics, Inc. · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Relay will present ASH data on all 32 patients from its dose randomization portion, after showing a 60% volumetric response rate across three doses at ISFA in May. Management models five and a half months of median PFS for CAPI. Pfizer supplies termociclib under a clinical trial supply agreement for a frontline trial due to start early next year.
Relay Therapeutics said cash, cash equivalents and investments of $848.6 million as of September 30, 2026 should fund operations into 2029. Nine-month net loss was $238.7 million, while zovegalisib received FDA Breakthrough Therapy designation with fulvestrant.
Relay Therapeutics reported full FDA approval of LYRFIGTU™ (lirafugratinib) for cholangiocarcinoma with FGFR2 fusion or other rearrangement, $848.6 million in cash and investments, and zovegalisib trial enrollment expected to complete in mid-2027.